News
Intrexon Depended on 1 Customer for 58% of First-Half 2017 Revenue Growth
The single biggest problem facing engineered biology conglomerate Intrexon (NYSE: XON) heading into the second quarter of 2017 was its dependency on small- and micro-cap companies for a significant
Why Impax Laboratories Inc Is Up for a Second Straight Day
Impax Laboratories (NASDAQ: IPXL) closed up 10% on Thursday after jumping 9.6% yesterday following its second-quarter earnings report. Today's move seems to be a continuation of yesterday's jump
Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters
It's been a crazy year for Organovo Holdings (NASDAQ: ONVO) so far. The 3D bioprinting company's former CEO abruptly left in April. Organovo disappointed investors with its fourth-quarter and
Why Impax Laboratories Inc Jumped Higher Today
Impax Laboratories (NASDAQ: IPXL) is up 7.6% at 11:53 a.m. EDT, having been up as much as 17.9% earlier today, after reporting solid second-quarter earnings.Revenue from the drugmaker was up 17% year
Here's Why NantKwest Inc. Tumbled 21.1% in July
Shares of NantKwest (NASDAQ: NK), a clinical-stage biotech company primarily focused on immunotherapy compounds that treat cancer, fell by 21% in July, according to S&P Global Market Intelligence. The
Here's What's Pushing Up Esperion Therapeutics Inc. Today
Shares of Esperion Therapeutics Inc. (NASDAQ: ESPR), a clinical-stage biotech focused on reducing cholesterol, popped up again this morning in response to top-line clinical trial results for its lead
Here's Why Inovio Pharmaceuticals, Inc. Sank 30.8% in July
Shares of Inovio Pharmaceuticals (NASDAQ: INO), a clinical-stage biotech focused on DNA immunotherapies and vaccines, fell by nearly a third in July, according to data from S&P Global Market
Here's Why Editas Medicine Rose as Much as 15.9% Monday
Shares of gene editing leader Editas Medicine (NASDAQ: EDIT) rose nearly 16% Monday on heavy trading volume, most of which occurred shortly after the market opened. The number of shares traded in the
BOIRON : Déclaration mensuelle des droits de vote au 31 juillet 2017
Le 8 août 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
Why Minerva Neurosciences Inc. Fell 31.1% in July
Shares of Minerva Neurosciences (NASDAQ: NERV), a clinical-stage biotech focused on diseases of the central nervous system, fell more than 31% in July, according to data from S&P Global Market
Why Flexion Therapeutics Shares Shot 12.8% Higher in July
After the company hosted an investor's day on July 10, shares in Flexion Therapeutics (NASDAQ: FLXN) jumped 12.8% last month, according to S&P Global Market Intelligence.Flexion Therapeutics doesn't
Here's Why Impax Laboratories Inc Jumped 18% In July
In response to receiving a double dose of good news from the Food and Drug Administration (FDA) and some bullish commentary from Wall Street, shares of Impax Laboratories (NASDAQ: IPXL), a maker of
3 Things You Need to Know About Marijuana Stock Cara Therapeutics
Cara Therapeutics (NASDAQ: CARA) announced its second-quarter financial results after the market closed on Thursday. The next day, Cara stock soared. But it wasn't because of the financial numbers
Here's Why Agenus Inc. Stock Slipped 13.6% in July
Shares of Agenus Inc. (NASDAQ: AGEN), a clinical-stage immuno-oncology company, fell 13.6% in July according to data from S&P Global Market Intelligence. Investors viewed a clinical-trial failure
Why Cara Therapeutics Shares Are Surging 23% Today
Cara Therapeutics' (NASDAQ: CARA) stock is surging 23% higher at 3:30 p.m. EDT today after management reported second-quarter financial results yesterday that included an update to its clinical-stage
Why Spectrum Pharmaceuticals Stock Is Bolting Higher Today
As of 1:28 p.m. EDT, shares of Spectrum Pharmaceuticals (NASDAQ: SPPI), a biotech developing treatments for various blood disorders and cancers, are up by over 21% on elevated volume. The drugmaker's
Here's Why PDL BioPharma Inc. Is Soaring Today
Shares of PDL BioPharma Inc. (NASDAQ: PDLI), a biopharma royalty company, are surging Friday in response to the positive second-quarter earnings report it issued after the bell Thursday. A quarterly
This Marijuana Stock Could Be 1 Clinical Trial Away From a $1 Billion Valuation
Few industries in the U.S. are growing at a quicker pace than legal marijuana. According to a fairly recent report from Marijuana Business Daily, entitled "Marijuana Business Factbook 2017," legal pot
Here's Why Curis, Inc. Dropped as Much as 14.5% This Morning
Shares of clinical-stage biopharma Curis, Inc. (NASDAQ: CRIS) dropped over 14% this morning after the company released second-quarter 2017 financial results and provided an update on a phase 2 trial
Here's Why Dynavax Technologies Corporation Stock Shot Up 64.2% in July
In July, a 12-to-1 Food and Drug Administration advisory committee vote in favor of Dynavax Technologies Corporation's (NASDAQ: DVAX) experimental hepatitis B vaccine allayed previous concerns that
Why Corcept Therapeutics Incorporated Stock Surged Higher Today
Shares of the rare-disease specialist Corcept Therapeutics Incorporated (NASDAQ: CORT) rose by 8.78% on heavy volume today, due to a stronger-than-expected second-quarter earnings report
Here's What Pushed ImmunoGen, Inc. Stock 16.5% Lower in July
Shares of ImmunoGen, Inc. (NASDAQ: IMGN), an oncology-focused biotech, dipped 16.5% lower in July according to data from S&P Global Market Intelligence. A fairly benign earnings report near the end of
3 Exciting Biotechs Under $30: Flexion Therapeutics' Response to the Opioid Epidemic
The opioid epidemic is a huge and tragic problem, and the market is starved for solutions. Flexion Therapeutics (NASDAQ: FLXN) is one company that's working on filling that gap and is close to
3 Biotech Stocks With Big News Coming
Clinical trial data and FDA decisions can cause biotech stocks to pop or drop, and that makes it critical for biotech investors to keep a close eye on Flexion Therapeutics (NASDAQ: FLXN), Keryx
These 2 Marijuana Stocks Moved in Completely Opposite Directions Last Week
In case you haven't noticed, marijuana stocks have been nothing short of unstoppable over the past year. As of a few weeks prior, the average marijuana stock with a market cap in excess of $200